Ergomed logo

ERGO - Ergomed News Story

788p 18.0  2.3%

Last Trade - 23/09/20

Sector
Healthcare
Size
Mid Cap
Market Cap £372.8m
Enterprise Value £363.9m
Revenue £68.3m
Position in Universe 586th / 1807

RCS - Ergomed plc - Key hire in pharmacoepidemiology services

Fri 25th May, 2018 7:01am
RNS Number : 2474P
Ergomed plc
25 May 2018
 

 PRESS RELEASE

 

 

Ergomed's PrimeVigilance adds specialist pharmacoepidemiology services with key hire

 

London, UK - 25 May 2018: Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce the addition of specialist pharmacoepidemiology services to PrimeVigilance's offering and the appointment of Dr Michael Forstner as Head of Risk Management and Pharmacoepidemiology.

 

In addition to the appointment of Dr Forstner, the ongoing contracts of Mesama Consulting, a Swiss-based consultancy founded in 2011 by Professor Jan-Willem van der Velden and most recently owned and managed by Dr Forstner, will be assigned to PrimeVigilance.

 

Dr Forstner is an expert in pharmacovigilance with significant experience in the planning, development, implementation and evaluation of risk management strategies, including post-authorisation studies, supporting the safe use of medicinal products. His skills will broaden Ergomed's premium service offering within PrimeVigilance, and build new revenue streams in pharmacoepidemiology and risk minimisation services, meeting high demand for these services.

 

Stephen Stamp, Chief Executive Officer of Ergomed plc, said: "I am delighted to welcome Michael to Ergomed with his significant experience in PV services, in addition to his unique expertise in pharmacoepidemiology and risk management strategies. His appointment will add value to our PrimeVigilance services as well as providing a bridge between CRO and PV, which fits perfectly in our strategy to leverage our expertise in pharmacovigilance and late phase clinical research, and build a new revenue stream in both our PV and specialist CRO services. We remain focused on growing both of our service offerings organically and through strategic acquisitions."

 

Ends

 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)




N+1 Singer (Joint Broker)

Tel: +44 (0) 20 7496 3000

Alex Price




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com



MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

 



 

About Ergomed

 

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes.  For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFKQDBPBKDFPB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.